Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Account Payables (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Change in Account Payables for 4 consecutive years, with -$983000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables rose 68.39% year-over-year to -$983000.0, compared with a TTM value of -$1.8 million through Sep 2025, up 58.03%, and an annual FY2024 reading of $687000.0, up 121.95% over the prior year.
  • Change in Account Payables was -$983000.0 for Q3 2025 at Atara Biotherapeutics, down from -$83000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.5 million in Q3 2023 and bottomed at -$4.6 million in Q1 2022.
  • Average Change in Account Payables over 4 years is -$1.0 million, with a median of -$983000.0 recorded in 2025.
  • The sharpest move saw Change in Account Payables surged 368.34% in 2024, then crashed 261.14% in 2025.
  • Year by year, Change in Account Payables stood at -$4.5 million in 2022, then surged by 36.85% to -$2.8 million in 2023, then skyrocketed by 179.12% to $2.2 million in 2024, then plummeted by 144.2% to -$983000.0 in 2025.
  • Business Quant data shows Change in Account Payables for ATRA at -$983000.0 in Q3 2025, -$83000.0 in Q2 2025, and -$3.0 million in Q1 2025.